Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder

Annals of Surgical Oncology

Volumn 20, Issue 7, 2013, Pages 2440-2445

  Keck, Bastian ^a   Wach, Sven ^a   Kunath, Frank ^a   Bertz, Simone ^b   Taubert, Helge ^a   Lehmann, Jan ^c   Stöckle, Michael ^d   Wullich, Bernd ^a   Hartmann, Arndt ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Urology Practice   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; UVOMORULIN; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CYSTECTOMY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROPAPILLARY UROTHELIAL CARCINOMA; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PLASMACYTOID UROTHELIAL CARCINOMA; PROTEIN DEPLETION; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; CADHERINS; CARCINOMA; CELL DIFFERENTIATION; CELL MEMBRANE; CELL NUCLEUS; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84878891425     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2709-4     Document Type: Article

References (25)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-81.
2. Eble J SG, Epstein JI, Sesterhenn IA, editors. Classification of tumours. Pathology and genetics of the tumours of the urinary system and male genital organs. Lyon: World Health Organization; 2004.
3. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 1993;53:3241-5. (Pubitemid 23223289)
4. Keck B, Stoehr R, Wach S, et al. The plasmacytoid carcinoma of the bladder - rare variant of aggressive urothelial carcinoma. Int J Cancer. 2011;129:346-54.
5. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol. 1993;142:987-93. (Pubitemid 24060574)
6. Eltz S, Comperat E, Cussenot O, Roupret M. Molecular and histological markers in urothelial carcinomas of the upper urinary tract. BJU Int. 2008;102:532-5.
7. Abraham S, Knapp DW, Cheng L, et al. Expression of EphA2 and ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res. 2006;12:353-60. (Pubitemid 43166121)
8. Keck B, Stoehr R, Wach S, et al. [Plasmacytoid and micropapillary urothelial carcinoma: rare forms of urothelial carcinoma]. Der Urologe Ausg A. 2011;50:217-20.
9. Lehmann J, Retz M, Wiemers C, et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol. 2005;23:4963-74. (Pubitemid 46224002)
10. Lim MG, Adsay NV, Grignon DJ, Osunkoya AO. E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma. Mod Pathol. 2011;24:241-7.
11. Sato K, Ueda Y, Kawamura K, Aihara K, Katsuda S. Plasmacytoid urothelial carcinoma of the urinary bladder: a case report and immunohistochemical study. Pathol Res Pract. 2009;205:189-94.
12. Oka H, Shiozaki H, Kobayashi K, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993;53:1696-701. (Pubitemid 23113254)
13. Becker KF, Atkinson MJ, Reich U, et al. Exon skipping in the E-cadherin gene transcript in metastatic human gastric carcinomas. Hum Mol Genet. 1993;2:803-4. (Pubitemid 23197530)
14. Becker KF, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994;54:3845-52. (Pubitemid 24241205)
15. Han AC, Soler AP, Tang CK, Knudsen KA, Salazar H. Nuclear localization of E-cadherin expression in Merkel cell carcinoma. Arch Pathol Lab Med. 2000;124:1147-51. (Pubitemid 30654805)
16. Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Oncol Metab. 2010;95:2334-42.
17. Elston MS, Gill AJ, Conaglen JV, et al. Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J Clin Oncol Metab. 2009;94:1436-42.
18. Chetty R, Serra S. Nuclear E-cadherin immunoexpression: from biology to potential applications in diagnostic pathology. Adv Anat Pathol. 2008;15:234-40.
19. Chetty R, Serra S, Asa SL. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors. Am J Surg Pathol. 2008;32:413-9. (Pubitemid 351398933)
20. Salahshor S, Naidoo R, Serra S, et al. Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. Mod Pathol. 2008;21:271-81. (Pubitemid 351304280)
21. Gervais ML, Henry PC, Saravanan A, et al. Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma. Lab Invest. 2007;87:1252-64. (Pubitemid 350126708)
22. Chetty R, Serra S. Membrane loss and aberrant nuclear localization of E-cadherin are consistent features of solid pseudopapillary tumour of the pancreas. An immunohistochemical study using two antibodies recognizing different domains of the E-cadherin molecule. Histopathology. 2008;52:325-30. (Pubitemid 351208060)
23. El-Bahrawy MA, Rowan A, Horncastle D, et al. E-cadherin/catenin complex status in solid pseudopapillary tumor of the pancreas. Am J Surg Pathol. 2008;32:1-7.
24. Roczniak-Ferguson A, Reynolds AB. Regulation of p120-catenin nucleocytoplasmic shuttling activity. J Cell Sci. 2003;116(Pt 20):4201-12. (Pubitemid 37337093)
25. van Hengel J, Vanhoenacker P, Staes K, van Roy F. Nuclear localization of the p120(ctn) Armadillo-like catenin is counteracted by a nuclear export signal and by E-cadherin expression. Proc Natl Acad Sci U S A. 1999;96:7980-85. (Pubitemid 29328393)